Kite Pharma Inc (KITE) 63.33 $KITE
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 4.25 (+0.03), BIIB: 269.16 (-10.72), NWBO: 6.16 (-0.08), CVM: 0.72 (-0.02), CLDX: 12.80 (+1.06), MACK: 9.60 (+0.17), INO: 6.16 (+0.20), NLNK: 34.31 (+1.42), JUNO: 48.64 (+0.84), GALE: 1.74 (+0.01), IMMU: 2.17 (+0.12), ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), SPPI: 6.20 (+0.07), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), SRNE: 8.61 (+0.05), ONTY: 2.88 (+0.08), IMUC: 0.44 (-0.01), PGNX: 5.77 (+0.26), ARGS: 5.79 (-0.19), GBIM: 2.54 (+0.02), BLCM: 14.65 (+0.39), SGEN: 39.38 (+0.87), KITE: 63.33 (+0.26), MRK: 50.95 (-0.07)
Kite Pharma Commends Steven A. Rosenberg, M.D., Ph.D., on the Prestigious Medal of Honor Award From the American Cancer Society
GlobeNewswire - Wed Oct 07, 7:00AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the National Cancer Institute (NCI) and a special advisor to Kite, has received three significant awards for his achievements and career dedicated to advancing cancer research. The American Cancer Society (ACS), the largest voluntary health organization in the United States, awarded Dr. Rosenberg its Medal of Honor for his pioneering leadership in cancer immunotherapy. The Medal of Honor is the ACS' highest honor and was presented to Dr. Rosenberg at a ceremony held in Washington, DC, on September 30, 2015. Additional recent awards include:
KITE: 63.33 (+0.26)
Global Indolent Lymphoma Pipeline Review, H2 2015 - 17 Companies & 25 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q2nmbb/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Altor BioScience Corporation - Astellas Pharma Inc. - Bayer AG - Biothera, Inc. - Boehringer Ingelheim GmbH - Celgene Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Juno Therapeutics Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - MorphoSys AG Drug Profiles - acalisib - ALT-803 - bendamustine hydrochloride - BI-836826 - CC-122 - copanlisib hydrochloride - DI-B4 - duvelisib - entospletinib - ibrutinib - idelalisib - Imprime PGG - INCB-39110 - INCB-40093 - INCB-50465 - JCAR-015 - KTE-C19 - lenalidomide - MEDI-0680 - MEDI-551 - MEDI-551 MEDI-0680 - MOR-208 - obinutuzumab - venetoclax - vorinostat For more information visit http://www.researchandmarkets.com/research/q2...t_lymphoma
KITE: 63.33 (+0.26), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), INCY: 105.00 (+1.56), JUNO: 48.64 (+0.84), INFI: 8.37 (+0.48), ABBV: 55.64 (-0.40), CELGZ: 1.74 (+0.04)
Kite Pharma Announces Peer-Reviewed Publication of T Cell Receptor Based Product Candidate to Treat HPV-Associated Cancers
GlobeNewswire - Thu Oct 01, 4:01AM CDT
- TCR product candidate targeting human papillomavirus (HPV)-16 E6 selectively kills cervical and head and neck cancer cells
KITE: 63.33 (+0.26)
Kite Pharma to Present at IBC Life Sciences' IMMUNO-ONCOLOGY: Advancing the Next Generation of Cancer Immunotherapies Conference
GlobeNewswire - Thu Sep 24, 6:59AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Marc Better Ph.D., Vice President, Product Sciences, will present during the opening plenary session at IBC Life Sciences' IMMUNO-ONCOLOGY: Advancing the Next Generation of Cancer Immunotherapies Conference, taking place in Alexandria, VA, September 30 - October 1, 2015. Dr. Better's presentation, "Overcoming Challenges for Engineered Autologous T Cell Therapy," will take place on Wednesday, September 30, 2015, at 8:15am Eastern Time. In addition, a podcast and article related to Dr. Better's participation in the upcoming event are available via the Calendar of Events section of Kite's website at ir.kitepharma.com.
KITE: 63.33 (+0.26)
Covered Call Alerts For PayPal, Bristol-Myers Squibb, KITE Pharma, Palo Alto Networks and VASCO Data Security Released By InvestorsObserver
PR Newswire - Mon Sep 21, 8:31AM CDT
InvestorsObserver has issued critical PriceWatch Alerts for PYPL, BMY, KITE, PANW, VDSI.
VDSI: 19.22 (+0.20), KITE: 63.33 (+0.26), PYPL: 32.06 (+0.39), BMY: 61.44 (+0.93), PANW: 171.88 (+2.29)
Biotechnology Equities under the Scanner -- Gilead Sciences, Aeterna Zentaris, RXi Pharma, BioCryst Pharma, and Kite Pharma
PR Newswire - Fri Sep 18, 8:10AM CDT
Equity Research Institute has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), Aeterna Zentaris Inc. (NASDAQ: AEZS), RXi Pharmaceuticals Corporation (NASDAQ: RXII), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), and Kite Pharma Inc. (NASDAQ: KITE). Free research report on Gilead Sciences can be accessed at https://www.erionline.net/reports?keyword=GILD On Thursday, September 17, 2015, the NASDAQ Composite ended at 4,893.95, up 0.10%, the Dow Jones Industrial Average edged 0.39% lower, to finish the day at 16,674.74, and the S&P 500 closed at 1,990.20, down 0.26%. The losses were broad based as five out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
BCRX: 8.80 (-0.95), RXII: 0.50 (+0.02), KITE: 63.33 (+0.26), GILD: 100.65 (-0.16), AEZS: 0.09 (unch)
Amgen to Acquire Dezima Pharma, Strikes Deal with Xencor
Zacks Equity Research - Zacks Investment Research - Thu Sep 17, 2:15PM CDT
Amgen (AMGN), to buy cardiovascular focused company, Dezima Pharma, strikes a deal with Xencor targeting areas of cancer immunotherapy and inflammation.
KITE: 63.33 (+0.26), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), XNCR: 12.28 (-0.13)
Amgen, Xencor In $1.75 Billion Cancer Drug Alliance
at Investor's Business Daily - Wed Sep 16, 7:02AM CDT
Small biotech Xencor (XNCR) said Wednesday that it had entered a cancer-drug collaboration with Amgen (AMGN) that could be worth as much as $1.75 billion. Amgen agreed to pay $45 million upfront to license Xencor's XmAb bispecific technology platform...
KITE: 63.33 (+0.26), AMGN: 149.59 (-0.31), JUNO: 48.64 (+0.84), ABBV: 55.64 (-0.40), XNCR: 12.28 (-0.13)
Franz B. Humer, Former Chairman and CEO of Roche Group, Appointed to Kite Pharma's Board of Directors
GlobeNewswire - Tue Sep 15, 2:00AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Dr. Franz B. Humer, the former Chairman and Chief Executive of Roche Holding Ltd., has been appointed to the Company's Board of Directors.
KITE: 63.33 (+0.26)
Will Kite (KITE) Get Orphan Status Again in EU for KTE-C19?
Arpita Dutt - Zacks Investment Research - Mon Sep 14, 1:56PM CDT
The COMP has adopted a positive opinion regarding the granting of orphan drug status to Kite's (KITE) KTE-C19 for the treatment of PMBCL and MCL.
BLUE: 88.80 (+0.30), GILD: 100.65 (-0.16), KITE: 63.33 (+0.26), AMGN: 149.59 (-0.31)
Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NKI)
GlobeNewswire - Mon Sep 14, 7:00AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that it has expanded its collaboration with the Netherlands Cancer Institute (NKI). Kite and the NKI have entered into an agreement under which Kite will receive from the NKI the exclusive option to license multiple T cell receptor (TCR) gene sequences for the development and commercialization of cancer immunotherapy candidates targeting solid tumors. Kite has also expanded its access to additional resources and research facilities through a master services agreement with the NKI.
KITE: 63.33 (+0.26)
Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite's Lead Cancer T-Cell Immunotherapy
GlobeNewswire - Fri Sep 11, 7:00AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE) announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending KTE-C19 for designation as an orphan medicinal product for the treatment of PMBCL and MCL. KTE-C19 is an investigational therapy in which a patient's T cells are genetically engineered to express a chimeric antigen receptor (CAR) designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. No other product candidate currently has orphan drug designation for the treatment of PMBCL in the EU. Kite previously received orphan drug designation for KTE-C19 for the treatment of diffuse large B-cell lymphoma (DLBCL) in both the US and the EU.
KITE: 63.33 (+0.26)
Bursting Biotechs -- Are These Stocks Buys?
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Tue Sep 08, 9:59AM CDT
Biotech is a favorite sector for us to talk about here at The Motley Fool, and with the recent hits the market has taken, some of these companies are looking like a steal. But are they worth jumping on board with during this downturn, or should we...
INSY: 25.65 (+0.64), KITE: 63.33 (+0.26), GILD: 100.65 (-0.16)
Critical Alerts For Ambarella, Kinder Morgan, JetBlue, Starbucks and Kite Pharma Released By InvestorsObserver
PR Newswire - Tue Sep 08, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMBA, KMI, JBLU, SBUX and KITE.
SBUX: 60.07 (+0.61), KMI: 32.35 (-0.33), AMBA: 57.17 (+1.01), KITE: 63.33 (+0.26), JBLU: 26.10 (+0.84)
Kite Pharma Commends Honors Conferred to Scientific Advisory Board Members for Their Significant Contributions to Medicine
GlobeNewswire - Thu Sep 03, 3:19PM CDT
-- Kite SAB Chair Dr. Owen Witte Reappointed to US Cancer Panel
KITE: 63.33 (+0.26)
Kite Pharma to Participate in Upcoming Investor Conferences in September 2015
GlobeNewswire - Thu Sep 03, 7:00AM CDT
Kite Pharma, Inc., (Nasdaq:KITE) today announced that the management team will participate in two upcoming investor conferences this month:
KITE: 63.33 (+0.26)
The Numbers Behind Biotech's Horrible, No Good, Awful August
at The Street - Tue Sep 01, 6:27AM CDT
Among all U.S.-listed biotech stocks, regardless of market cap, only 68 companies managed to end August with higher stock prices, while 267 biotech stocks lost ground.
BLUE: 88.80 (+0.30), ZIOP: 10.92 (+0.32), OPK: 8.90 (+0.26), NK: 13.09 (-0.21), KITE: 63.33 (+0.26), ONCE: 49.30 (+1.86), CLDX: 12.80 (+1.06), XON: 36.01 (+1.24), IBB: 308.45 (+1.25), JUNO: 48.64 (+0.84), TWTR: 30.85 (+0.53), MNKD: 3.05 (+0.04)
Critical Alerts For Gilead Sciences, Kite Pharma, Valero Energy, Starbucks and Nokia Corporation Released By InvestorsObserver
PR Newswire - Tue Aug 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, KITE, VLO, SBUX and NOK.
SBUX: 60.07 (+0.61), VLO: 64.20 (-1.51), KITE: 63.33 (+0.26), GILD: 100.65 (-0.16), NOK: 6.98 (-0.06)
Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio
at The Street - Fri Aug 21, 4:55AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 88.80 (+0.30), INO: 6.16 (+0.20), GBT: 48.39 (+0.31), KITE: 63.33 (+0.26), PFE: 33.24 (+0.15), MRK: 50.95 (-0.07), CLDX: 12.80 (+1.06), AZN: 32.23 (-0.16), JUNO: 48.64 (+0.84)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 4.25 (+0.03), BIIB: 269.16 (-10.72), NWBO: 6.16 (-0.08), CVM: 0.72 (-0.02), CLDX: 12.80 (+1.06), MACK: 9.60 (+0.17), INO: 6.16 (+0.20), NLNK: 34.31 (+1.42), JUNO: 48.64 (+0.84), GALE: 1.74 (+0.01), IMMU: 2.17 (+0.12), ADXS: 11.07 (+0.83), ADRO: 22.06 (+0.32), IMGN: 10.91 (+0.25), AMGN: 149.59 (-0.31), SPPI: 6.20 (+0.07), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), SRNE: 8.61 (+0.05), ONTY: 2.88 (+0.08), IMUC: 0.44 (-0.01), PGNX: 5.77 (+0.26), ARGS: 5.79 (-0.19), GBIM: 2.54 (+0.02), BLCM: 14.65 (+0.39), SGEN: 39.38 (+0.87), KITE: 63.33 (+0.26), MRK: 50.95 (-0.07)
Kite Pharma Commends Steven A. Rosenberg, M.D., Ph.D., on the Prestigious Medal of Honor Award From the American Cancer Society
GlobeNewswire - Wed Oct 07, 7:00AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the National Cancer Institute (NCI) and a special advisor to Kite, has received three significant awards for his achievements and career dedicated to advancing cancer research. The American Cancer Society (ACS), the largest voluntary health organization in the United States, awarded Dr. Rosenberg its Medal of Honor for his pioneering leadership in cancer immunotherapy. The Medal of Honor is the ACS' highest honor and was presented to Dr. Rosenberg at a ceremony held in Washington, DC, on September 30, 2015. Additional recent awards include:
KITE: 63.33 (+0.26)
Global Indolent Lymphoma Pipeline Review, H2 2015 - 17 Companies & 25 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q2nmbb/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Altor BioScience Corporation - Astellas Pharma Inc. - Bayer AG - Biothera, Inc. - Boehringer Ingelheim GmbH - Celgene Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Juno Therapeutics Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - MorphoSys AG Drug Profiles - acalisib - ALT-803 - bendamustine hydrochloride - BI-836826 - CC-122 - copanlisib hydrochloride - DI-B4 - duvelisib - entospletinib - ibrutinib - idelalisib - Imprime PGG - INCB-39110 - INCB-40093 - INCB-50465 - JCAR-015 - KTE-C19 - lenalidomide - MEDI-0680 - MEDI-551 - MEDI-551 MEDI-0680 - MOR-208 - obinutuzumab - venetoclax - vorinostat For more information visit http://www.researchandmarkets.com/research/q2...t_lymphoma
KITE: 63.33 (+0.26), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), INCY: 105.00 (+1.56), JUNO: 48.64 (+0.84), INFI: 8.37 (+0.48), ABBV: 55.64 (-0.40), CELGZ: 1.74 (+0.04)
Kite Pharma Announces Peer-Reviewed Publication of T Cell Receptor Based Product Candidate to Treat HPV-Associated Cancers
GlobeNewswire - Thu Oct 01, 4:01AM CDT
- TCR product candidate targeting human papillomavirus (HPV)-16 E6 selectively kills cervical and head and neck cancer cells
KITE: 63.33 (+0.26)
Kite Pharma to Present at IBC Life Sciences' IMMUNO-ONCOLOGY: Advancing the Next Generation of Cancer Immunotherapies Conference
GlobeNewswire - Thu Sep 24, 6:59AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Marc Better Ph.D., Vice President, Product Sciences, will present during the opening plenary session at IBC Life Sciences' IMMUNO-ONCOLOGY: Advancing the Next Generation of Cancer Immunotherapies Conference, taking place in Alexandria, VA, September 30 - October 1, 2015. Dr. Better's presentation, "Overcoming Challenges for Engineered Autologous T Cell Therapy," will take place on Wednesday, September 30, 2015, at 8:15am Eastern Time. In addition, a podcast and article related to Dr. Better's participation in the upcoming event are available via the Calendar of Events section of Kite's website at ir.kitepharma.com.
KITE: 63.33 (+0.26)
Covered Call Alerts For PayPal, Bristol-Myers Squibb, KITE Pharma, Palo Alto Networks and VASCO Data Security Released By InvestorsObserver
PR Newswire - Mon Sep 21, 8:31AM CDT
InvestorsObserver has issued critical PriceWatch Alerts for PYPL, BMY, KITE, PANW, VDSI.
VDSI: 19.22 (+0.20), KITE: 63.33 (+0.26), PYPL: 32.06 (+0.39), BMY: 61.44 (+0.93), PANW: 171.88 (+2.29)
Biotechnology Equities under the Scanner -- Gilead Sciences, Aeterna Zentaris, RXi Pharma, BioCryst Pharma, and Kite Pharma
PR Newswire - Fri Sep 18, 8:10AM CDT
Equity Research Institute has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), Aeterna Zentaris Inc. (NASDAQ: AEZS), RXi Pharmaceuticals Corporation (NASDAQ: RXII), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), and Kite Pharma Inc. (NASDAQ: KITE). Free research report on Gilead Sciences can be accessed at https://www.erionline.net/reports?keyword=GILD On Thursday, September 17, 2015, the NASDAQ Composite ended at 4,893.95, up 0.10%, the Dow Jones Industrial Average edged 0.39% lower, to finish the day at 16,674.74, and the S&P 500 closed at 1,990.20, down 0.26%. The losses were broad based as five out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
BCRX: 8.80 (-0.95), RXII: 0.50 (+0.02), KITE: 63.33 (+0.26), GILD: 100.65 (-0.16), AEZS: 0.09 (unch)
Amgen to Acquire Dezima Pharma, Strikes Deal with Xencor
Zacks Equity Research - Zacks Investment Research - Thu Sep 17, 2:15PM CDT
Amgen (AMGN), to buy cardiovascular focused company, Dezima Pharma, strikes a deal with Xencor targeting areas of cancer immunotherapy and inflammation.
KITE: 63.33 (+0.26), GILD: 100.65 (-0.16), AMGN: 149.59 (-0.31), XNCR: 12.28 (-0.13)
Amgen, Xencor In $1.75 Billion Cancer Drug Alliance
at Investor's Business Daily - Wed Sep 16, 7:02AM CDT
Small biotech Xencor (XNCR) said Wednesday that it had entered a cancer-drug collaboration with Amgen (AMGN) that could be worth as much as $1.75 billion. Amgen agreed to pay $45 million upfront to license Xencor's XmAb bispecific technology platform...
KITE: 63.33 (+0.26), AMGN: 149.59 (-0.31), JUNO: 48.64 (+0.84), ABBV: 55.64 (-0.40), XNCR: 12.28 (-0.13)
Franz B. Humer, Former Chairman and CEO of Roche Group, Appointed to Kite Pharma's Board of Directors
GlobeNewswire - Tue Sep 15, 2:00AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Dr. Franz B. Humer, the former Chairman and Chief Executive of Roche Holding Ltd., has been appointed to the Company's Board of Directors.
KITE: 63.33 (+0.26)
Will Kite (KITE) Get Orphan Status Again in EU for KTE-C19?
Arpita Dutt - Zacks Investment Research - Mon Sep 14, 1:56PM CDT
The COMP has adopted a positive opinion regarding the granting of orphan drug status to Kite's (KITE) KTE-C19 for the treatment of PMBCL and MCL.
BLUE: 88.80 (+0.30), GILD: 100.65 (-0.16), KITE: 63.33 (+0.26), AMGN: 149.59 (-0.31)
Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NKI)
GlobeNewswire - Mon Sep 14, 7:00AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that it has expanded its collaboration with the Netherlands Cancer Institute (NKI). Kite and the NKI have entered into an agreement under which Kite will receive from the NKI the exclusive option to license multiple T cell receptor (TCR) gene sequences for the development and commercialization of cancer immunotherapy candidates targeting solid tumors. Kite has also expanded its access to additional resources and research facilities through a master services agreement with the NKI.
KITE: 63.33 (+0.26)
Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite's Lead Cancer T-Cell Immunotherapy
GlobeNewswire - Fri Sep 11, 7:00AM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE) announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending KTE-C19 for designation as an orphan medicinal product for the treatment of PMBCL and MCL. KTE-C19 is an investigational therapy in which a patient's T cells are genetically engineered to express a chimeric antigen receptor (CAR) designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. No other product candidate currently has orphan drug designation for the treatment of PMBCL in the EU. Kite previously received orphan drug designation for KTE-C19 for the treatment of diffuse large B-cell lymphoma (DLBCL) in both the US and the EU.
KITE: 63.33 (+0.26)
Bursting Biotechs -- Are These Stocks Buys?
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Tue Sep 08, 9:59AM CDT
Biotech is a favorite sector for us to talk about here at The Motley Fool, and with the recent hits the market has taken, some of these companies are looking like a steal. But are they worth jumping on board with during this downturn, or should we...
INSY: 25.65 (+0.64), KITE: 63.33 (+0.26), GILD: 100.65 (-0.16)
Critical Alerts For Ambarella, Kinder Morgan, JetBlue, Starbucks and Kite Pharma Released By InvestorsObserver
PR Newswire - Tue Sep 08, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AMBA, KMI, JBLU, SBUX and KITE.
SBUX: 60.07 (+0.61), KMI: 32.35 (-0.33), AMBA: 57.17 (+1.01), KITE: 63.33 (+0.26), JBLU: 26.10 (+0.84)
Kite Pharma Commends Honors Conferred to Scientific Advisory Board Members for Their Significant Contributions to Medicine
GlobeNewswire - Thu Sep 03, 3:19PM CDT
-- Kite SAB Chair Dr. Owen Witte Reappointed to US Cancer Panel
KITE: 63.33 (+0.26)
Kite Pharma to Participate in Upcoming Investor Conferences in September 2015
GlobeNewswire - Thu Sep 03, 7:00AM CDT
Kite Pharma, Inc., (Nasdaq:KITE) today announced that the management team will participate in two upcoming investor conferences this month:
KITE: 63.33 (+0.26)
The Numbers Behind Biotech's Horrible, No Good, Awful August
at The Street - Tue Sep 01, 6:27AM CDT
Among all U.S.-listed biotech stocks, regardless of market cap, only 68 companies managed to end August with higher stock prices, while 267 biotech stocks lost ground.
BLUE: 88.80 (+0.30), ZIOP: 10.92 (+0.32), OPK: 8.90 (+0.26), NK: 13.09 (-0.21), KITE: 63.33 (+0.26), ONCE: 49.30 (+1.86), CLDX: 12.80 (+1.06), XON: 36.01 (+1.24), IBB: 308.45 (+1.25), JUNO: 48.64 (+0.84), TWTR: 30.85 (+0.53), MNKD: 3.05 (+0.04)
Critical Alerts For Gilead Sciences, Kite Pharma, Valero Energy, Starbucks and Nokia Corporation Released By InvestorsObserver
PR Newswire - Tue Aug 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, KITE, VLO, SBUX and NOK.
SBUX: 60.07 (+0.61), VLO: 64.20 (-1.51), KITE: 63.33 (+0.26), GILD: 100.65 (-0.16), NOK: 6.98 (-0.06)
Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio
at The Street - Fri Aug 21, 4:55AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 88.80 (+0.30), INO: 6.16 (+0.20), GBT: 48.39 (+0.31), KITE: 63.33 (+0.26), PFE: 33.24 (+0.15), MRK: 50.95 (-0.07), CLDX: 12.80 (+1.06), AZN: 32.23 (-0.16), JUNO: 48.64 (+0.84)
